University of Groningen First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial

Citation for published version (APA): Jongsma, M. E., Aardoom, M. A., Cozijnsen, M., van Pieterson, M., de Meij, T., Groeneweg, M., Norbruis, O., Wolters, V. M., van Wering, H., Hojsak, I., Kolho, K-L., Hummel, T., Stapelbroek, J. M., van der Feen, C., Rheenen, van, P., van Wijk, M. P., Tecklenburg-Roord, T. A., Schreurs, M. W. J., Rizopoulos, D., ... de Ridder, L. (2020). First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut, [gutjnl-2020-322339]. https://doi.org/10.1136/gutjnl-2020-322339